Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The efficacy of novel strategies to improve the immunogenicity to the vaccine, such as the use of adjuvanted vaccines, boosting doses and intradermal vaccination, needs to be validated in ...

Its lead program GT-30, an intradermal vaccine administered in combination with anti-PD1 therapy (pembrolizumab), is in phase 1b/2a testing for patients with advanced hepatocellular carcinoma.